Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Alzinova. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Alzinova's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Alzinova has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare Alzinova's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Alzinova's earnings growth to the Sweden market average as no estimate data is available.
Unable to compare Alzinova's revenue growth to the Sweden market average as no estimate data is available.
Unable to determine if Alzinova is high growth as no earnings estimate data is available.
Unable to determine if Alzinova is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Alzinova's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Kristina Torfgård Ph.D. serves as CEO at Alzinova AB since 2019. She serves as Vice President & Global Project Head at Albireo AB. Dr. Torfgård served as Vice President of Clinical & Regulatory Affairs of Albireo AB since February 2015 until February 2016. Dr. Torfgård has experience in drug development covering the full product lifecycle from pre-clinical evaluation, through clinical development, launch and life cycle management in pharmaceutical and biotech industry. Her experience covers multiple therapeutic and disease areas eg gastrointestinal, neuroscience, cardiovascular and metabolic disease/diabetes. At AstraZeneca, she worked several years in the clinical organization, held different senior and global leadership roles. Dr. Torfgård holds a MSc in Pharmacy and a PhD in Clinical Pharmacology. She studied PhD in Medical Science, Clinical Pharmacology at Linköping University from 1988 to 1992. She studied MSc Pharmacy at Uppsala University from 1984 to 1992.
Insufficient data for Kristina to compare compensation growth.
Insufficient data for Kristina to establish whether their remuneration is reasonable compared to companies of similar size in Sweden.
Management Team Tenure
Average tenure of the
management team in years:
The average tenure for the Alzinova management team is less than 2 years, this suggests a new team.
Chief Executive Officer
Co-Founder & Chief Scientific Officer
Chief Financial Officer
Chief Medical Officer
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the Alzinova board of directors is less than 3 years, this suggests a new board.
Board of Directors
Co-Founder & Chief Scientific Officer
Who owns this company?
Recent Insider Trading
No 3 month open market individual insider trading information.
For example, a Harvard University study found that 'insider purchases earn abnormal returns of more than 6% per year.' Check out our latest analysis for Alzinova The Last 12 Months Of Insider Transactions At Alzinova In the last twelve months, the biggest single purchase by an insider was when Chief Executive Officer Per Wester bought kr571k worth of shares at a price of kr14.94 per share. … It is encouraging to see an insider paid above the current price for shares, as it suggests they saw value, even at higher levels. … OM:ALZ Recent Insider Trading, July 25th 2019 Insider Ownership of Alzinova I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders.
Do Insiders Own Lots Of Shares In Alzinova AB (STO:ALZ)?
Our analysis of the ownership of the company, below, shows that institutional investors have bought into the company. … See our latest analysis for Alzinova OM:ALZ Ownership Summary, July 4th 2019 What Does The Institutional Ownership Tell Us About Alzinova? … General Public Ownership The general public -- mostly retail investors -- own 65% of Alzinova.
So the share price itself impacts the value of the shares (as it determines the cost of capital). … The TSR is a return calculation that accounts for the value of cash dividends (assuming that any dividend received was reinvested) and the calculated value of any discounted capital raisings and spin-offs. … We note that Alzinova's TSR, at -20% is higher than its share price return of -23%.
Have Insiders Been Buying Alzinova AB (STO:ALZ) Shares?
So we'll take a look at whether insiders have been buying or selling shares in Alzinova AB (STO:ALZ). … But logic dictates you should pay some attention to whether insiders are buying or selling shares. … Alzinova Insider Transactions Over The Last Year.
What Kind Of Shareholder Owns Most Alzinova AB (STO:ALZ) Stock?
Every investor in Alzinova AB (STO:ALZ) should be aware of the most powerful shareholder groups. … I quite like to see at least a little bit of insider ownership. … With a market capitalization of kr203m, Alzinova is a small cap stock, so it might not be well known by many institutional investors.
Alzinova AB, a biotechnology company, engages in the discovery and development of therapeutics for the treatment of Alzheimer’s disease in Sweden. It focuses on developing ALZ-101, an oligomer-directed vaccine; and ALZ-201, a monoclonal antibody that is used for the treatment of oligomeric Aß. The company was founded in 2011 and is based in Gothenburg, Sweden.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.